Researchers at Northwestern University in Chicago have made significant advancements in the delivery of CRISPR technology, which has the potential to transform genetic medicine. The team developed a new nanostructure called lipid nanoparticle spherical nucleic acids (LNP-SNAs) that enhances CRISPR's ability to enter cells by threefold compared to standard delivery methods.
CRISPR, a powerful genetic editing tool, requires an effective delivery system to reach and penetrate cells. Traditionally, lipid nanoparticles have been used, but they often experience inefficiencies and toxicity. The newly designed LNP-SNAs consist of a core that carries CRISPR components, such as the Cas9 enzyme, surrounded by a dense shell of DNA. This structure not only facilitates entry into various cell types but also reduces toxicity and increases the efficiency of gene editing.
In laboratory tests involving human and animal cells, the LNP-SNAs demonstrated a remarkable improvement in both cellular uptake and the success rate of DNA repairs, exceeding current methods by over 60%. The study underscores the significance of the structural design of nanomaterials in maximizing their effectiveness.
Chad A. Mirkin, who led the research, emphasized that the efficiency of CRISPR delivery is critical for its application in treating genetic disorders. The study results have been published in the Proceedings of the National Academy of Sciences, highlighting the growing field of structural nanomedicine.
The next steps involve further validation of this delivery system in animal disease models, with an eye towards clinical applications. The technology is being commercialized by Flashpoint Therapeutics, a biotechnology startup, indicating a move towards potential therapeutic use in genetic medicine.